Microdosing starts at fractions of the lowest prescribed dose and stops that titration early, maintaining a subtherapeutic dose long-term
Instead, clinicians should acknowledge this risk and consider individualized risk-benefit strategies when prescribing GLP-1 RAs, particularly for patients with pre-existing ocular manifestations and must inform patients regarding possible ocular hazards while advocating for regular retinal examinations and assessments of visual acuity
Dehau, T., Cherlet, M., Croubels, S., Van Immerseel, F., & Goossens, E
Halminen J, Sattar N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes
Avoiding late-night eating aligns with your body's circadian rhythm, potentially supporting hormonal responses including GLP-1 release
If you have a family history of thyroid cancer, you shouldnt take liraglutide